Is the Patent Office Forcing Race into Biotechnology Patents?
By Jonathan Kahn, Biopolitical Times guest contributor
| 06. 14. 2011
A review of recent patent applications to the United States Patent and Trademark Office (PTO) has uncovered a highly problematic new practice: PTO examiners are requiring applicants to include racial categories in the claims sections of some biotechnology patent submissions, where they provide the basis for subsequent research, development, and marketing of products developed from the patent.
In a recent article in Nature Biotechnology, I explore the general contours of this phenomenon, which first came to light in a December 2008 presentation by PTO Quality Assurance Specialist Kathleen Bragdon titled “A Look at Personalized Medicine.” Taking an example of a treatment for breast cancer, the presentation argued that in cases where effectiveness for all races was not established, “a scope of enablement rejection must be considered.” In other words, the patent could cover only those racial groups that had been included in the underlying study. The implication was that race must be considered a genetically salient factor in biotechnology patent applications.
The critical responses Bragdon’s presentation prompted could have led the PTO to reconsider the relevance...
Related Articles
By Lisa C. Ikemoto, Los Angeles Times | 07.07.2022
A few days after the Supreme Court overturned Roe vs. Wade, Boston IVF, a fertility company with centers in six states, posted a statement that speaks to the havoc this decision will wreak not just for abortions, but for...
Several new opinion polls on human biotechnology issues have recently come to our attention and two of them are discussed here. As is all too typical of polling on these complex matters, it is not clear that respondents were aware of, or informed about, key background information that would shield them from drawing false conclusions, as discussed below. (For summaries of these and older opinion polls on topics related to heritable human genome editing and cloning or genetically modifying animals...
By Antonio Regalado, MIT Technology Review | 07.12.2022
A volunteer in New Zealand has become the first person to undergo DNA editing in order to lower their blood cholesterol, a step that may foreshadow wide use of the technology to prevent heart attacks.
The experiment, part of a...
By Carissa Wong, New Scientist | 07.01.2022
Photo by CDC on Unsplash
A new form of the genome-editing technique CRISPR could provide a more accurate way to edit mutations that cause genetic diseases. The approach, which was tested in fruit flies, fixes a genetic mutation on one...